CTIS2024-514603-34-00进行中（未招募）1 期
Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy - INTERMEDIATE-01
Centre Francois Baclesse0 个研究点目标入组 476 人开始时间: 2024年5月22日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 476
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined as follows according to TNM 2017: oPapillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid cancer (FTC) (with < 4 foci of vascular invasion) or Hürthle cell carcinoma (HCC) oT1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and/or pN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes = 10 oT1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes = 10, •Signed informed consent form, •Patient who agrees to be followed annually during 5 years, •Patient affiliated to the French social security system, •Patient treated by total thyroidectomy with macroscopically complete tumor resection (R0 or R1) ± neck dissection, •Total thyroidectomy performed within 6 to 14 weeks before randomization, •Patient with or without anti-thyroglobulin antibodies (TgAb), •No known distant metastases, •Normal post-operative neck ultrasound (US) or if doubtful US, negative cytology and normal Tg value (<10 ng/ml) in FNA washout fluid, •Post-operative LT4 treatment initiated at least 6 weeks before randomization, •Performance Status 0 or 1, •Patients aged 18 years or older
排除标准
- •Patients with: omedullary or anaplastic thyroid cancer oor poorly differentiated carcinoma oor well differentiated FTC with at least 4 foci of vascular invasion oor PTC with aggressive variants (tall cell or columnar cell carcinoma, diffuse sclerosing papillary, hobnail variant) oNIFTP (Noninvasive follicular thyroid neoplasm with papillary-like nuclear features), •History of malignancy in the past 3 years, except skin cancer excluding melanoma, carcinoma in situ of the cervix. Any other solid tumor or lymphoma (without bone marrow involvement) must have been treated and not have shown signs of recurrence for at least 3 years, •Low-risk or high-risk DTC patients according to ATA 2015, and intermediate-risk patients with extra-thyroid extension into the perithyroidal muscles (pT3b according to pTNM 2017), and/or pN1 with nodal largest dimension >10 mm or with extra-capsular invasion or more than 10 metastatic nodes. This excludes the following patients: oAll pT3 or pT4 opT1aN0/x with or without minimal extra-thyroid extension opT1bN0/x, pT2N0/Nx without minimal extra-thyroid extension opT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension <2mm opT1aN1 or pT1bN1 or pT2N1 without extra-thyroid extension and with nodal largest dimension >10mm oSurgery considered as macroscopically incomplete (R2), •Patients who have undergone lobectomy only, •Post-operative neck US with metastatic lymph-nodes confirmed by cytology or by increased Tg (>10 ng/ml) in FNA washout fluid, •Drugs affecting thyroid function including iodinated contrast agents in the 6 weeks prior to randomization. Amiodarone should have been stopped at least 1 year before randomization., •Previous RAI treatment for thyroid cancer, •Pregnant or lactating women, •Any associated geographical, social or psychopathological condition that could compromise the patient's ability to participate in the study, •Patient deprived of liberty or placed under the authority of a tutor
研究者
相似试验
招募中
3 期
Multicentric phase III trial comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphyintermediate-risk differentiated thyroid cancer patients2024-514603-34-00Centre Francois Baclesse476
进行中（未招募）
1 期
Study to compare efficacy of two strategies of rituximab administration du rituximab (rituximab sub cutaneous versus rituximab intravenous) in patients with previously untreated follicular lymphoma.Stage II-IV follicular lymphoma grade 1-3a not previously treatedMedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000004864EUCTR2014-000128-22-FRYSARC223
招募中
1 期
Studying Conditioning Regimen In Pediatric Transplantation -AMAcute Myeoloid LeukemiaCTIS2023-505512-37-00Vaestra Goetalandsregionen103
进行中（未招募）
1 期
Studying Conditioning Regimen In Pediatric Transplantation – AMAcute myeloid leukemia (AML) in childrenEUCTR2021-003282-36-NOVästra Götalands Regionen230
进行中（未招募）
1 期
Studying Conditioning Regimen In Pediatric Transplantation – AMAcute myeloid leukemia (AML) in childrenEUCTR2021-003282-36-NLVästra Götalands Regionen230